Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.57 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | CCKAR | P32238 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400996 | 0.86 | NHERF1 (0.76) | NHERF1NPC1RAB9ARXFP1KDM4E | |
| SCHEMBL6401163 | 0.86 | NHERF1 (0.56) | TP53POLBNHERF1NPC1RAB9A | |
| SCHEMBL6400705 | 0.85 | TP53 (0.60) | TP53POLBNHERF1PIN1PDGFRB | |
| SCHEMBL6402485 | 0.82 | NHERF1 (0.60) | TP53POLBNHERF1NPC1RAB9A | |
| SCHEMBL14845689 | 0.80 | TP53 (1.00) | TP53POLBPIN1PDGFRBPDGFRA | |
| SCHEMBL6399671 | 0.79 | TP53 (0.53) | TP53POLBPIN1PDGFRBPDGFRA | |
| SCHEMBL6402193 | 0.79 | NHERF1 (0.68) | NHERF1NPC1RAB9ARXFP1FLT3 | |
| SCHEMBL6401120 | 0.78 | NHERF1 (0.71) | NHERF1NPC1RAB9ARXFP1KDM4E | |
| SCHEMBL6405483 | 0.77 | TP53 (0.50) | TP53POLBPIN1PDGFRBPDGFRA | |
| SCHEMBL6402489 | 0.77 | NHERF1 (0.56) | TP53POLBNHERF1RXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | TP53 1043/4885POLB 4755/4885NHERF1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.